Loading

Annals of Pediatrics and Child Health

Neuronal Ceroid Lipofuscinoses: Why Early Diagnosis Matters?

Editorial | Open Access

  • 1. Department of Pediatric Genetics, Albert Einstein College of Medicine, Island
+ Show More - Show Less
Corresponding Authors
Milen Velinov, Department of Human Genetics, NYS Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Rd, Staten Island, NY 10314, Island, Tel: 0-718-494-5219; Fax: 1-718-494-1072
CITATION

Velinov M (2014) Neuronal Ceroid Lipofuscinoses: Why Early Diagnosis Matters? Ann Pediatr Child Health 2(2): 1016.

EDITORIAL

Neuronal Ceroid Lipofuscinoses (NCL) are a group of progressive neurodegenerative disorders leading to early death. NCL as a group is considered to be the most common neurodegenerative disorder with childhood onset [1,2]. 14 distinct NCL types have been identified and are indicated as CLN 1 trough CLN 14. For 13 of them the genetic defect has been identified. To-date no genetic defect has been identified for CLN 9 disease. NCL types differ by their age of onset and disease course (Figure 1). A unifying feature of all types is the presence of characteristic autofluorescent lysosomal storage material referred to as lipofuscin. The lipofuscinosis is most prominent in neuronal cells, but is also observed in other cellular types. Clinically most NCL types start with progressive vision loss, which is followed by cognitive decline, seizures and early death. In types CLN 4, 12 and 13 no vision impairment is observed. All NCL are with autosomal recessive inheritance with the exception of the autosomal-dominant, adult-onset CLN 4 disease. The reported incidence of NCL varies quite significantly in different countries and ranges from 1.3 to 7 in 100,000 live births. The most common types, CLN 1, 2 and 3 represent the vast majority of the cases. All the remaining types are uncommon. Specific storage inclusions are observed in various peripheral cells in all NCL types using Electron Microscopy (EM) [3]. Study of patient’s peripheral cells for such EM inclusions may be done as an initial laboratory screening test when NCL is suspected. In types CLN1,2 and 10 the protein products are soluble lysosomal enzymes. Clinical enzyme activity assays were developed for diagnostic confirmation of CLN 1 and 2 [4,5]. General diagnostic algorithms for determining the particular NCL type have been suggested [1,2]. More recently, Next Generation Sequencing based diagnostic panels including most NCL genes have been developed. Such panels are becoming more popular in the diagnostic evaluation of suspected NCL patients because of the high degree of clinical overlap between different NCL types. In addition, the EM study may be with lower diagnostic efficacy in the adult-onset forms [6,7]. Currently three US-based and two Europe-based laboratories listed on “Genetests.org” website offer such NCL gene panel testing [8].

Strategies for specific therapy have been in development for the common types – CLN 1, 2 and 3. NCL exclusively affect the Central Nervous System (CNS), and every potentially effective treatment should be able to reach the brain cells. The blood brain barrier prevents the passage of most large molecules when applied peripherally. It is thus difficult to deliver the deficient gene or protein via the peripheral circulation. Accordingly, the clinical trials that aim to introduce such large molecules have relied on direct CNS delivery. In addition, many of the deficient protein products, most notably the product of the gene CLN3 are membrane bound and insoluble. This makes the correction of such protein deficits impossible by delivering a normal copy of the mutant gene or of its protein product because the protein molecule is insoluble and would not reach the deficient cells. Despite these difficulties several clinical trials for NCL are currently in progress. Several different strategies for specific treatment are currently being evaluated:

• Gene Therapy: Direct CNS delivery of an AAV vector that incorporates the CLN2 gene has been promising in animal models of CLN2 disease [9]. A human clinical trial using this approach is conducted at Cornell University and is currently recruiting participants [10].

• Enzyme Replacement Therapy: A clinical trial for the direct delivery of the CLN2 product - the lysosomal enzyme TTP1 is carried by the company Biomarin and is currently recruiting patients [11].

• Substrate Reduction Therapy: The deficiency of the CLN1 protein product (the lysosomal enzyme PPT1) leads to lysosomal accumulation of cysteine

thioesters. The agent Cystagon was found to inhibit the formation of this storage material. A pilot treatment trial with PO Cystagon in four patients with atypical, later onset CLN1 disease was carried by our group during seven years. The participants’ disease progression was compared to five untreated controls with the same mutations. While no significant differences in the disease course was noted with the treatment, some symptomatic improvement was observed in one of the participants for whom a higher Cystagon dose was achieved [12]. In addition, no serious side effects were observed. Another trial using N-Acetylcysteine along with Cystagon in younger typical CLN 1 patients was recently completed, but no results of this trial have been published to-date [13].

• Immune Modulation: Neuroimmune alterations were shown to be part of the disease pathway in CLN 3 disease using an animal model [14]. Currently a clinical trial for patients with CLN 3 disease using the immune modulator Mycophenolate Mofetil is conducted at the University of Rochester. This trial is recruiting patients [15]. Development of a secondary site for this trial in our Institute is underway.

For the inclusion in such clinical trials, a confirmed molecular defect is a necessary pre-condition. Patients with advanced stages of NCL may not be eligible for inclusion. This emphasizes the importance of early diagnosis of NCL. The paradigm of supportive only treatment for NCL is changing and early molecular diagnosis has become imperative for these patients. Such early diagnosis may make it possible to refer the patient for inclusion in a clinical trial. In addition an early molecular diagnosis would make prenatal diagnosis available for future pregnancies in these families.

ACKNOWLEDGEMENT

This work is partially supported by the New York State Office of People with Developmental Disabilities.

REFERENCES

1. Mole SE, Williams RE. Neuronal Ceroid-Lipofuscinoses. 2001 Oct 10 [Updated 2013 Aug 1]. In: Pagon RA, Adam MP, Ardinger HH, et al editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle. 1993-2014.

2. Schulz A, Kohlschütter A, Mink J, Simonati A, Williams R . NCL diseases - clinical perspectives. Biochim Biophys Acta. 2013; 1832: 1801-1806.

3. Anderson GW, Smith VV, Brooke I, Malone M, Sebire NJ . Diagnosis of neuronal ceroid lipofuscinosis (Batten disease) by electron microscopy in peripheral blood specimens. Ultrastruct Pathol. 2006; 30: 373-378.

4. Anderson GW, Smith VV, Brooke I, Malone M, Sebire NJ . Diagnosis of neuronal ceroid lipofuscinosis (Batten disease) by electron microscopy in peripheral blood specimens. Ultrastruct Pathol. 2006; 30: 373-378.

5. Voznyi YV, Keulemans JL, Mancini GM, Catsman-Berrevoets CE, Young E, Winchester B, et al. A new simple enzyme assay for pre- and postnatal diagnosis of infantile neuronal ceroid lipofuscinosis (INCL) and its variants. J Med Genet. 1999; 36: 471-474.

6. Junaid MA, Sklower Brooks S, Wisniewski KE, Pullarkat RK. A novel assay for lysosomal pepstatin-insensitive proteinase and its application for the diagnosis of late-infantile neuronal ceroid lipofuscinosis. Clin Chim Acta. 1999; 281: 169-176.

7. Velinov M, Dolzhanskaya N, Gonzalez M, Powell E, Konidari I, Hulme W, et al. Mutations in the gene DNAJC5 cause autosomal dominant Kufs disease in a proportion of cases: study of the Parry family and 8 other families. 2012; 7: e29729

8. Velinov M, Dolzhanskaya N, Gonzalez M, Powell E, Konidari I, Hulme W, et al. Mutations in the gene DNAJC5 cause autosomal dominant Kufs disease in a proportion of cases: study of the Parry family and 8 other families. PLoS One. 2012; 7: e29729.

9. Dolzhanskaya N, Gonzalez MA, Sperziani F, Stefl S, Messing J, Wen GY, et al. A novel p.Leu(381)Phe mutation in presenilin 1 is associated with very early onset and unusually fast progressing dementia as well as lysosomal inclusions typically seen in Kufs disease. J Alzheimers Dis. 2014; 39:23-27

10. Neuronal Ceroid-Lipofuscinoses.

11. Sondhi D, Johnson L, Purpura K, Monette S, Souweidane MM, Kaplitt MG, et al. Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther Methods. 2012 Oct;23: 324-35.

12. Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis. 2014 13.Safety and Efficacy Study of BMN190 for the Treatment of Patients With CLN2 Disease. 2014.

14. Gavin M, Wen GY, Messing J, Adelman S, Logush A, Jenkins EC, et al. Substrate Reduction Therapy in Four Patients with Milder CLN1 Mutations and Juvenile-Onset Batten Disease Using Cysteamine Bitartrate. JIMD Rep. 2013; 11: 87-92.

15. Gavin M, Wen GY, Messing J, Adelman S, Logush A, Jenkins EC, et al. Substrate Reduction Therapy in Four Patients with Milder CLN1 Mutations and Juvenile-Onset Batten Disease Using Cysteamine Bitartrate. JIMD Rep. 2013; 11: 87-92.

16. Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis. 2014. 17.Lim MJ, Alexander N, Benedict JW, Chattopadhyay S, Shemilt SJ, Guérin CJ, et al. IgG entry and deposition are components of the neuroimmune response in Batten disease. Neurobiol Dis. 2007; 25: 239-251.

18. Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JUMP). 2014.

Velinov M (2014) Neuronal Ceroid Lipofuscinoses: Why Early Diagnosis Matters? Ann Pediatr Child Health 2(2): 1016.

Received : 01 Jul 2014
Accepted : 19 Jul 2014
Published : 21 Jul 2014
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X